WordNet
- any solution that is injected (as into the skin) (同)injectant
- the act of putting a liquid into the body by means of a syringe; "the nurse gave him a flu shot" (同)shot
- the forceful insertion of a substance under pressure
PrepTutorEJDIC
- 〈U〉〈C〉注射,注入 / 〈C〉注射液
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review).
- Watanabe M1, Nasu Y1, Kumon H2.Author information 1Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Okayama 700-8558, Japan ; Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Okayama 700-8558, Japan.2Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Okayama 700-8558, Japan.AbstractReduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3 is a tumor suppressor and therapeutic gene and has been studied with respect to the application of cancer gene therapy. Our previous studies demonstrated that the intratumoral injection of an adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC) suppresses tumor growth in mouse models of prostate, breast and testicular cancer and malignant mesothelioma. The mechanisms underlying these antitumor therapeutic effects have only been clarified recently. It has been demonstrated that Ad-REIC treatment inhibits cancer progression via the upregulation of systemic anticancer immunity. Under experimental conditions, autologous cancer vaccination via cancer-specific apoptosis and anticancer immune activation is a possible therapeutic mechanism. The robust anticancer effects observed in previous preclinical studies support the clinical utility of Ad-REIC. At present, a phase I-IIa study of Ad-REIC gene therapy in prostate cancer patients is ongoing. The current study reviews the observations of previous fundamental studies and summarizes the anticancer mechanisms of intratumoral Ad-REIC treatment in terms of cancer vaccination.
- Oncology letters.Oncol Lett.2014 Mar;7(3):595-601. Epub 2013 Dec 27.
- Reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3 is a tumor suppressor and therapeutic gene and has been studied with respect to the application of cancer gene therapy. Our previous studies demonstrated that the intratumoral injection of an adenovirus vector carrying the human REIC/D
- PMID 24527065
- In vitro and in vivo evaluation of injectable implants for intratumoral delivery of 5-fluorouracil.
- Chen W1, Wu Z, Yang H, Guo S, Li D, Cheng L.Author information 1School of Pharmacy, Shanghai Jiao Tong University , Shanghai , China.AbstractThe aim of this study was to evaluate poly (ε-caprolactone) (PCL)-based injectable implants, which could achieve sustained release of 5-fluorouracil (5-FU) directly to tumors. The implants were prepared by injection molding and the effects of drug loading and poly (ethylene glycol) (PEG) as additive on drug release were investigated. Two implants (PCL/5-FU25% and PCL/PEG5%/5-FU25%) were selected for in vivo evaluation regarding drug distribution in tumor, plasma concentration and antitumor effect. In vitro release test showed that drug release duration varied from 18 to 565 h depending on the compositions of the implant. After intratumoral injection, in vivo release of 5-FU from implants PCL/5-FU25% and PCL/PEG5%/5-FU25% were apparently accelerated. The maximum drug concentrations in tumor were sevenfold and ninefold higher than that attained by intraperitoneal (i.p.) administration of 5-FU solution for the implants PCL/5-FU25% and PCL/PEG5%/5-FU25%, respectively. Drug concentration in plasma was always below 0.1 μg/ml over the entire experimental period. Additionally, the two implants exhibited better tumor growth inhibition as shown by the results that their tumor volumes were approximately twofold smaller than those treated by i.p. administration after 7 days. The present study demonstrated that the injectable 5-FU-loaded implants could minimize drug systemic exposure and exert desirable antitumor activity.
- Pharmaceutical development and technology.Pharm Dev Technol.2014 Mar;19(2):223-31. doi: 10.3109/10837450.2013.769568. Epub 2013 Feb 25.
- The aim of this study was to evaluate poly (ε-caprolactone) (PCL)-based injectable implants, which could achieve sustained release of 5-fluorouracil (5-FU) directly to tumors. The implants were prepared by injection molding and the effects of drug loading and poly (ethylene glycol) (PEG) as additiv
- PMID 23432601
- A specific STAT3-binding peptide exerts anti-proliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling.
- Kim D1, Lee IH, Kim S, Choi M, Kim H, Ahn S, Saw PE, Jeon H, Lee Y, Jon S.Author information 1Department of Biological Sciences, KAIST.AbstractSTAT3 promotes the survival, proliferation, metastasis, immune escape and drug resistance of cancer cells, making its targeting an appealing prospect. However, while multiple inhibitors of STAT3 and its regulatory or effector pathway elements have been developed, bioactive agents have been somewhat elusive. In this report, we report the identification of a specific STAT3-binding peptide (APTSTAT3) through phage display of a novel 'aptide' library. APTSTAT3 bound STAT3 with high specificity and affinity (~231 nM). Addition of a cell-penetrating motif to the peptide to yield APTSTAT3-9R enabled uptake by murine B16F1 melanoma cells. Treatment of various types of cancer cells with APTSTAT3-9R blocked STAT3 phosphorylation and reduced expression of STAT targets, including cyclin D1, Bcl-xL, and survivin. As a result, APTSTAT3-9R suppressed the viability and proliferation of cancer cells. Furthermore, intratumoral injection of APTSTAT3-9R exerted potent antitumor activity in both xenograft and allograft tumor models. Our results offer a preclinical proof of concept for APTSTAT3 as a tractable agent for translation to target the broad array of cancers harbouring constitutively activated STAT3.
- Cancer research.Cancer Res.2014 Feb 27. [Epub ahead of print]
- STAT3 promotes the survival, proliferation, metastasis, immune escape and drug resistance of cancer cells, making its targeting an appealing prospect. However, while multiple inhibitors of STAT3 and its regulatory or effector pathway elements have been developed, bioactive agents have been somewhat
- PMID 24576829
Japanese Journal
- 大畑 賀央,中原 理恵,笠井 尚,神山 由香理,五十嵐 誠治,森 清志,児玉 哲郎
- 気管支学 : 日本気管支研究会雑誌 34(1), 80-84, 2012-01-25
- 背景.腫瘍片の喀出という稀な経過をたどった多形癌の1切除例を経験したので報告する.症例.71歳,男性.血痰を主訴に近医を受診,精査加療目的に当院紹介となった.胸部CT検査では右下葉に結節影を認め,この一部が下葉気管支内に進展していた.気管支鏡検査では右下葉支入口部にポリープ状の腫瘍を認め,病理組織検査にて多形癌の疑いと診断された.心臓精査終了後に気管支鏡検査を再度施行したところ,腫瘍先端はポリープ …
- NAID 110009327987
- Phase ? trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients
- Endo Hisahito,Saito Takuro,Kenjo Akira [他]
- Journal of hepato-biliary-pancreatic sciences : official journal of the Japanese Society of Hepato-Biliary-Pancreatic Surgery, the Asian-Pacific Hepato-Pancreato-Biliary Association, the Japan Biliary Association 19(4), 465-475, 2012
- NAID 40019353815
Related Links
- The direct intratumoral (i.t.) injection of anticancer agents has been evaluated extensively in the past few decades. Thus far, however, it has failed to become established as an alternative route of administration in routine ...
- Intratumoral injection of the vectors provides an important safety advantage over i.v. injection (11), because the vector infects predominantly the cells of the injected tumor instead of liver cells (Fig. 2). Many types of human tumor i ...
Related Pictures
★リンクテーブル★
[★]
- 英
- intratumoral injection
- 関
- 腫瘍内局所投与
[★]
- 英
- intratumoral injection
- 関
- 腫瘍内投与
[★]
- 関
- congestive、engorgement、hyperaemia、hyperemia、infuse、infusion、inject、injectable、injectables、instill、shot、transfuse、transfusion
[★]
- 関
- intratumor
[★]
- 関
- intratumoral